Phase 1 Trial of GFH375 in KRAS G12D-Mutated Solid Tumors
Published in Nature Medicine in September 2026, a phase 1 clinical trial evaluating the oral, dual on-off binding KRAS G12D inhibitor GFH375 demonstrates encouraging response rates in patients with non-small … Read More